Demonstrating a Precision Medicine Approach to Targeting APOE4 Homozygotes to Treat the Multivariate Pathologies of Alzheimer’s Disease
Time: 11:30 am
day: Conference Day Two - Track Two
Details:
- Outlining the rationale for using APOE2 to develop a more specific genetic medicine
- Showcasing the ability of LX1001 to supplement levels of APOE2
- Reviewing the clinical data across all four dose cohorts
